Get the Stockscreener App
3.64
7.06%
0.24
After Hours:
3.53
-0.11
-3.02%
Macrogenics Inc stock is traded at $3.64, with a volume of 562.51K.
It is up +7.06% in the last 24 hours and up +4.30% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
See More
Previous Close:
$3.40
Open:
$3.45
24h Volume:
562.51K
Relative Volume:
0.88
Market Cap:
$222.50M
Revenue:
$56.91M
Net Income/Loss:
$-9.06M
P/E Ratio:
30.33
EPS:
0.12
Net Cash Flow:
$-79.97M
1W Performance:
+10.98%
1M Performance:
+4.30%
6M Performance:
-20.00%
1Y Performance:
-52.42%
1-Day Range:
$3.43
$3.68
1-Week Range:
$3.15
$3.68
52-Week Range:
$2.9511
$21.88
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.64 | 222.50M | 56.91M | -9.06M | -79.97M | 0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Connor Clark & Lunn Investment Management Ltd. Increases Position in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
MacroGenics appoints new financial officer - Investing.com
MacroGenics Announces Leadership Transition in Financial Roles - TipRanks
Analysts Set MacroGenics, Inc. (NASDAQ:MGNX) PT at $7.63 - MarketBeat
MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates - MSN
MacroGenics' SWOT analysis: biotech stock faces pipeline hurdles amid cash strength - Investing.com India
MacroGenics downgraded to market perform by JMP, price target removed - MSN
FY2024 Earnings Estimate for MacroGenics Issued By B. Riley - MarketBeat
StockNews.com Upgrades MacroGenics (NASDAQ:MGNX) to Buy - MarketBeat
MacroGenics FY2024 EPS Estimate Increased by HC Wainwright - MarketBeat
Leerink Partnrs Increases Earnings Estimates for MacroGenics - MarketBeat
MacroGenics puts the brakes on vobra duo development - The Pharma Letter
MacroGenics downgraded to Market Perform from Outperform at JMP Securities - TipRanks
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights - Benzinga
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2024 Earnings Call Transcript - Insider Monkey
MacroGenics (NASDAQ:MGNX) Rating Lowered to "Market Perform" at JMP Securities - MarketBeat
MacroGenics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire
MacroGenics (MGNX) to Present at Guggenheim and Stifel Healthcare Conferences | MGNX Stock News - StockTitan
Earnings call: MacroGenics reports a revenue jump to $110.7 million By Investing.com - Investing.com South Africa
Earnings call: MacroGenics reports a revenue jump to $110.7 million - Investing.com India
MacroGenics Margenza rights sale a positive, says Leerink - TipRanks
MacroGenics (NASDAQ:MGNX) Receives Neutral Rating from HC Wainwright - MarketBeat
MacroGenics Inc earnings beat by $0.69, revenue topped estimates - Investing.com Australia
Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments - GuruFocus.com
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - GlobeNewswire
MacroGenics Inc. Reports Strong Revenue Growth - TipRanks
MacroGenics: Q3 Earnings Snapshot - Barchart
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript - Nasdaq
Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings - Yahoo Finance
MacroGenics Q3 2024 Earnings Preview - MSN
Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Effective February 28, 2025 - Marketscreener.com
Q3 2024 MacroGenics Inc Earnings Call Transcript - GuruFocus.com
Macrogenics Earnings Preview - Benzinga
Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result - GuruFocus.com
MacroGenics (NASDAQ:MGNX) Lowered to Sell Rating by StockNews.com - MarketBeat
Masashi Miyamoto to become chairman and CEO of Kyowa Kirin - BioCentury
MacroGenics CEO Scott Koenig to resign early next year - Investing.com India
MacroGenics Announces Leadership Transition - GlobeNewswire
MacroGenics (MGNX) Scheduled to Post Earnings on Tuesday - MarketBeat
MacroGenics Co-Founder Koenig Stepping Down as President, CEO - MarketWatch
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):